Short paper

Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle

Christina A Pacak^1,2 , Thomas Conlon^1,2 , Cathryn S Mah^1,3 and Barry J Byrne^1,2,3

¹  Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA

²  Department of Pediatrics, University of Florida, Gainesville, FL, USA

³  Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL, USA

author email corresponding author email

Genetic Vaccines and Therapy 2008, 6:14doi:10.1186/1479-0556-6-14

Published:	15 October 2008

Abstract

The purpose of this study was to assess the behavior of pseudotyped recombinant adeno-associated virus type 1 (rAAV2/1) vector genomes in dystrophic skeletal muscle. A comparison was made between a therapeutic vector and a reporter vector by injecting the hindlimb in a mouse model of Limb Girdle Muscular Dystrophy Type 2D (LGMD-2D) prior to disease onset. We hypothesized that the therapeutic vector would establish long-term persistence through prevention of myofiber turnover. In contrast, the reporter vector genome copy number would diminish over time due to disease-associated muscle degradation.

One day old alpha sarcoglycan knockout mice (sgca^-/-) were injected with 1 × 10¹¹ vector genomes of rAAV2/1-tMCK-sgca in one hindlimb and the same dose of rAAV2/1-tMCK-LacZ in the contra lateral hindlimb. Newborn mice are tolerant of the foreign transgene allowing for long-term expression of both the marker and the therapeutic gene in the null background. At 2 time-points following vector administration, hindlimb muscles were harvested and analyzed for LacZ or sarcoglycan expression. Our data demonstrate prolonged vector genome persistence in skeletal muscle from the hindlimbs injected with the therapeutic transgene as compared to hindlimbs injected with the reporter gene. We observed loss of vector genomes in skeletal muscles that were there were not protected by the benefits of therapeutic gene transfer. In comparison, the therapeutic vector expressing sarcoglycan led to reduction or elimination of myofiber loss. Mitigating the membrane instability inherent in dystrophic muscle was able to prolong the life of individual myofibers.